Market Research Report
Klebsiella infections - Pipeline Insight, 2021
|Klebsiella infections - Pipeline Insight, 2021|
DelveInsight Business Research LLP
Content info: 60 Pages
Delivery time: 2-10 business days
DelveInsight's, "Klebsiella infections - Pipeline Insight, 2021," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Klebsiella infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Klebsiella is a type of bacteria commonly found in nature. In humans, the bacteria are often present in parts of the digestive tract where they do not generally cause problems. In the United States, Klebsiella pneumoniae and Klebsiella oxytoca are the two strains responsible for most human illnesses. Many Klebsiella infections are acquired in the hospital setting or in long-term care facilities. In fact, Klebsiellae account for up to 8% of all hospital-acquired infections. People with a compromised immune system and/or people who have an implanted medical device (such as a urinary catheter or airway tube) are more at risk for Klebsiella infections. Extensive use of antibiotics has resulted in the development of antibiotic-resistant strains of Klebsiella. These infections can be more aggressive and difficult to treat
"Klebsiella infections - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Klebsiella infections pipeline landscape is provided which includes the disease overview and Klebsiella infections treatment guidelines. The assessment part of the report embraces, in depth Klebsiella infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Klebsiella infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Klebsiella infections R&D. The therapies under development are focused on novel approaches to treat/improve Klebsiella infections.
This segment of the Klebsiella infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Klebsiella infections Emerging Drugs
BX003 targets bacterial strains of Klebsiella pneumoniae present in the gut of IBD and PSC patients. In two separate animal studies, different Klebsiella pneumoniae strains were shown to increase disease severity: colitis in IBD models and elevated liver enzymes and fibrosis in PSC models. The suggested underlying mechanism is induction of pro-inflammatory responses characteristic of these diseases, suggesting that these strains may have a role in the onset and aggravation of these diseases (see publication in Science and in Nature Microbiology). These strains were also shown to cause gut permeability or a "leaky gut" that may lead to inflammation in gut in IBD patients and microbial infection of bile ducts, resulting in inflammation and fibrosis within the liver of PSC patients. BX003 is characterized by a broad bacterial host range targeting Klebsiella pneumoniae strains present in the gut of both IBD and PSC patients. A Phase 1b/2a study aimed at evaluating the efficacy of BX003 in reduction of bacterial target with expected results by the end of H2 2022.
LimmaTech Biologics is developing Klebsiella pneumoniae tetravalent bioconjugate vaccine. LimmaTech Biologics uses a proprietary in vivo enzyme-based production method that alleviates the issues associated with the chemical conjugation process. At the core of this approach is a bacterial enzyme capable of forming precise linkages between glycan and protein moieties. The versatility of this platform combined with our extensive glycoengineering experience enables the development of innovative vaccines for multiple pathogens that has not been possible previously. Kleb4V is currently in Phase I/II stage of development.
This segment of the report provides insights about the different Klebsiella infections drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 15+ key companies which are developing the therapies for Klebsiella infections. The companies which have their Klebsiella infections drug candidates in the most advanced stage, i.e. phase I/II include, LimmaTech Biologics.
DelveInsight's report covers around 15+ products under different phases of clinical development like:
Klebsiella infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
Products have been categorized under various Molecule types such as:
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Klebsiella infections therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Klebsiella infections drugs.